-       Report 
   - August 2025
    -  182 Pages 
    Global
   
   From       €3181EUR$3,545USD£2,792GBP 
      €3535EUR$3,939USD£3,102GBP 
                  -       Report 
   - August 2025
    -  195 Pages 
    Global
   
   From       €3181EUR$3,545USD£2,792GBP 
      €3535EUR$3,939USD£3,102GBP 
                  -       Clinical Trials 
   - April 2025
    -  60 Pages 
    Global
   
   From       €1077EUR$1,200USD£945GBP 
      €1346EUR$1,500USD£1,181GBP 
                  -       Report 
   - December 2024
    -  90 Pages 
    Global
   
   From       €1723EUR$1,920USD£1,512GBP 
      €2154EUR$2,400USD£1,890GBP 
                -       Report 
   - September 2025
    -  313 Pages 
    Global
   
   From       €4442EUR$4,950USD£3,898GBP 
                 -       Report 
   - May 2025
    -  90 Pages 
    Global
   
   From       €5339EUR$5,950USD£4,686GBP 
                -       Report 
   - February 2025
    -  100 Pages 
    Global
   
   From       €5339EUR$5,950USD£4,686GBP 
                -       Report 
   - January 2025
    -  100 Pages 
    Global
   
   From       €5339EUR$5,950USD£4,686GBP 
                -       Report 
   - December 2024
    -  100 Pages 
    Global
   
   From       €5339EUR$5,950USD£4,686GBP 
                  -       Report 
   - October 2025
    -  188 Pages 
    Global
   
   From       €3181EUR$3,545USD£2,792GBP 
      €3535EUR$3,939USD£3,102GBP 
                  -       Report 
   - October 2025
    -  189 Pages 
    Global
   
   From       €3181EUR$3,545USD£2,792GBP 
      €3535EUR$3,939USD£3,102GBP 
                  -       Report 
   - October 2025
    -  193 Pages 
    Global
   
   From       €3181EUR$3,545USD£2,792GBP 
      €3535EUR$3,939USD£3,102GBP 
                  -       Report 
   - August 2025
    -  189 Pages 
    Global
   
   From       €3181EUR$3,545USD£2,792GBP 
      €3535EUR$3,939USD£3,102GBP 
                  -       Report 
   - August 2025
    -  195 Pages 
    Global
   
   From       €3181EUR$3,545USD£2,792GBP 
      €3535EUR$3,939USD£3,102GBP 
                  -       Report 
   - October 2025
    -  184 Pages 
    Global
   
   From       €3181EUR$3,545USD£2,792GBP 
      €3535EUR$3,939USD£3,102GBP 
                -       Report 
   - November 2025
    -  280 Pages 
    Global
   
   From       €5249EUR$5,850USD£4,607GBP 
                -       Report 
   - September 2025
    -  250 Pages 
    Global
   
   From       €4029EUR$4,490USD£3,536GBP 
                -       Report 
   - September 2025
    -  250 Pages 
    Global
   
   From       €4029EUR$4,490USD£3,536GBP 
                -       Report 
   - March 2025
    -  200 Pages 
    Global
   
   From       €4029EUR$4,490USD£3,536GBP 
                -       Report 
   - March 2025
    -  200 Pages 
    Global
   
   From       €4029EUR$4,490USD£3,536GBP 
             
         Somatostatin is a peptide hormone that is used in the treatment of various types of cancer. It is used to inhibit the release of growth hormones, which can help reduce the size of tumors. It is also used to reduce the side effects of chemotherapy and radiation therapy. Somatostatin is available in both injectable and oral forms. It is often used in combination with other drugs to treat cancer.
Somatostatin is used to treat a variety of cancers, including pancreatic, prostate, and neuroendocrine    tumors. It is also used to treat acromegaly, a condition caused by excessive growth hormone production. Somatostatin is also used to treat Cushing's syndrome, a condition caused by excessive cortisol production.
Some companies that produce somatostatin include Novartis, Merck, and Pfizer. Other companies that produce somatostatin-based drugs include Ipsen, Teva, and Sandoz. Show Less   Read more